Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently...
Hence then, the article about vicebio next generation vaccine biotech to be acquired by sanofi for us 1 6 billion was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion )
Also on site :
- ‘The Voice’s Kayleigh Matthews Stuns Coaches With Four-Chair Turn on Vince Gill Cover
- Martha Stewart’s Stylish Stoneware Food Container Set Is Perfect for Leftovers, and Just $25 Ahead of Prime Day
- ‘Riverdance’ & ‘Lord of the Dance’ Fans Shocked as Michael Flatley Shares His Wife’s Death at 52: What Happened?